PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2013.45.3.1782013453178-185How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single InstitutionBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heohttp://www.e-crt.org/upload/pdf/crt-45-178.pdf, http://www.e-crt.org/upload/pdf/crt-45-178.pdf
Lung Cancer10.1016/s0169-5002(08)70080-1200860S25The use of gefitinib in the management of non small cell lung cancer: a single institution experienceA. Srivastava, A.R.A. Razak, J. Gardiner, G. Mazdai, A. Hugheshttps://api.elsevier.com/content/article/PII:S0169500208700801?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500208700801?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(95)90640-11995132212Outcome of pneumonectomy for primary non-small cell lung cancer — A ten-year experiencehttps://api.elsevier.com/content/article/PII:0169500295906401?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500295906401?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(13)70019-9201379S719 A single centre experience of gefitinib in patients with EGFR mutation positive non small cell lung cancerH.S. Walter, D.A. Fennell, S.I. Ahmedhttps://api.elsevier.com/content/article/PII:S0169500213700199?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500213700199?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(18)30104-12018115S32Erlotinib in non-small lung cancer: a single institution experienceS.A.J. Rizvi, H. Eldeebhttps://api.elsevier.com/content/article/PII:S0169500218301041?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500218301041?httpAccept=text/plain
Clinical Lung Cancer10.1016/s1525-7304(11)70473-9200564214-216Clinical Development of Gefitinib in Non–Small-Cell Lung Cancer and the Iressa® Survival Evaluation in Lung Cancer TrialNancy Price, Chandra P. Belanihttps://api.elsevier.com/content/article/PII:S1525730411704739?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411704739?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(09)70262-4200964S58139P ERLOTINIB VERSUS GEFITINIB TREATMENT FOR NON-SMALL CELL LUNG CANCER (NSCLC): A SINGLE INSTITUTION EXPERIENCE IN KOREAS.Y. Lee, J.H. Kim, K.H. In, H.K. Kim, S.E. Kim, Y.K. Kim, H.S. Yong, K.H. Kang, D.Y. Kang, D.S. Yanghttps://api.elsevier.com/content/article/PII:S0169500209702624?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500209702624?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(00)80409-22000291123Chemotherapy for metastatic non-small cell lung cancer (NSCLC): A single institution experience in BrazilJ.R Pereira, S.J Martins, F.K Ikari, S.M Nikaedohttps://api.elsevier.com/content/article/PII:S0169500200804092?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500200804092?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(13)70306-4201380S3886P PROGNOSTIC FACTORS IN METASTATIC NON SMALL CELL LUNG CANCER: A SINGLE INSTITUTION EXPERIENCEZ. Benbrahim, L. Amaadour, S. Arifi, N. Abda, C. Nejjari, N. Mellas, O. El Mesbahihttps://api.elsevier.com/content/article/PII:S0169500213703064?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500213703064?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(13)70302-7201380S36-S3782P COMBINED MODALITY THERAPY OF ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTION EXPERIENCEB. Resulihttps://api.elsevier.com/content/article/PII:S0169500213703027?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500213703027?httpAccept=text/plain